Newsfeeds - Spark Newswire

2 minute read

Biogen Announces Topline Results From Phase 2 Study Of Gosuranemab; Says Did Not Meet Primary Efficacy Endpoint Of Change From Baseline At Week 78

Today, 12:51 PM

Biogen Inc. (NASDAQ:BIIB) today announced topline results from its Phase 2 TANGO study of gosuranemab (BIIB092), an investigational anti-tau antibody that was being evaluated as a potential treatment for

BIIB

1 minute read

First Patient Set To Receive Biogen’s Alzheimer’s Drug: Reuters

By Vandana Singh

Today, 12:51 PM

A U.S. hospital on Wednesday will give the first infusion of Biogen Inc’s (NASDAQ:BIIB) expensive, controversial Alzheimer’s drug approved a week…

BIIB

1 minute read

Tesla And Biogen Lead The SPY Lower Tuesday

By Henry Khederian

Today, 12:51 PM

U.S. indices were trading lower Tuesday as investors await an outcome from this week's Fed meeting.

BABA

2 minute read

Biogen Analyst Raises Price Target On Higher Chance Of Success For Depression Drug

By Shanthi Rexaline

Today, 12:51 PM

Biogen Inc.

BIIB

1 minute read

Why Sage Therapeutics (SAGE) Stock Is Falling Despite Meeting Primary Endpoint In Major Depressive Disorder Trial With Zuranolone

By Vandana Singh

Today, 12:51 PM

Looking to make a comeback after a big Phase 3 flop, Sage Therapeutics Inc (NASDAQ:SAGE) revealed data from another Phase 3…

BIIB

6 minute read

The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda

By Shanthi Rexaline

Today, 12:51 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 14)

ACHL

1 minute read

Sage Therapeutics – Biogen’s Zuranolone Tops Placebo In Reducing Depressive Symptoms

By Vandana Singh

Today, 12:51 PM

Sage Therapeutics Inc (NASDAQ:SAGE) and Biogen Inc (NASDAQ: BIIB) have announced data from WATERFALL Phase 3 study evaluating zuranolone (SAGE-217/BIIB125) in patients with Major…

BIIB

6 minute read

Sage Therapeutics And Biogen Announce Pivotal Phase 3 Results For Zuranolone In Major Depressive Disorder; Study Met Primary Endpoint

By Bill Haddad

Today, 12:51 PM

At the Day 15 primary endpoint, zuranolone 50 mg showed a statistically significant and clinically meaningful reduction in depressive symptoms as measured by HAMD-17 (p=0.0141) compared to placebo Rapid onset of

BIIB

1 minute read

Yet Another Biogen’s Retinal Disease Gene Therapy Fails In Late-Stage Study

By Vandana Singh

Today, 12:51 PM

While basking in the glow of the approval for its Alzheimer’s treatment, Biogen Inc (NASDAQ:BIIB) announced that a gene therapy candidate…

BIIB

1 minute read

Biogen Announces Phase 3 STAR Study Of BIIB111/AAV2-REP1 In Choroideremia Did Not Meet Primary Or Key Secondary Endpoints

By Bill Haddad

Today, 12:51 PM

Biogen Inc. (NASDAQ:BIIB) today announced topline results from the Phase 3 STAR study of timrepigene emparvovec (BIIB111/AAV2-REP1), an investigational gene therapy for the potential treatment of choroideremia. The STAR

BIIB